Drugs Made In America Acquisition Corp. (DMAA) Stock Statistics & Valuation Metrics

Drugs Made In America Acquisition Corp. has a market cap or net worth of $246.01M. The enterprise value is $342.61M.

Drugs Made In America Acquisition Corp. has 33,517,143 shares outstanding. The number of shares has decreased by -2.65% in one year.

Drugs Made In America Acquisition Corp.’s return on equity (ROE) is 1.97 and return on invested capital (ROIC) is -8.88%.

The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.

In the last 12 months, Drugs Made In America Acquisition Corp. had revenue of 0.00 and earned ― in profits. Earnings per share was -0.06.

In the last 12 months, operating cash flow was -251.37K and capital expenditures 0.00, giving a free cash flow of -251.37K billion.

Drugs Made In America Acquisition Corp. pays an annual dividend of ―, resulting in a dividend yield of ―

Drugs Made In America Acquisition Corp. upcoming earnings date is ―, ―.

Drugs Made In America Acquisition Corp. as a current ratio of 6.27, with Debt / Equity ratio of 0.03%

In the past 12 months, Drugs Made In America Acquisition Corp. has paid 0.00 in taxes.

Drugs Made In America Acquisition Corp. EV to EBITDA ratio is 0.00, with an EV/FCF ratio of -291.63.

Drugs Made In America Acquisition Corp. has $923.00 in cash and marketable securities with $60.90K in debt, giving a net cash position of $59.98K billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Drugs Made In America Acquisition Corp. is ―, which is 11.43% higher than the current price. The consensus rating is ―